|
|
||||||||
Technical Briefs |
Departments of
1
Physiology,
2
Pathology,
3
Respirology, and
4
Biochemistry, Queens University, and
5
Kingston General Hospital, Kingston, Ontario, K7L 3N6 Canada;
6
Internal Medicine, Sagamihara Kyodo Hospital, Hashimoto 2-8-18, Sagamihara, Kanagawa 229, Japan
aauthor for correspondence: Queens University, Department of Physiology, Kingston, Ontario, K7L 3N6 Canada; fax 613-533-6880, e-mail jve1@post.queensu.ca
| The first 20% of the full text of this article appears below. |
Unlike the extensive research devoted to the development of troponin-based diagnostic assays for myocardial disease, much less effort has been expended on the development of a counterpart for skeletal muscle disorders. The consensus that the cardiac troponins [cardiac troponin I (cTnI) and/or cTnT] should be used for diagnosis of myocardial infarction (MI), as well as for diagnosis and management of unstable angina, is based on their superior tissue specificity over such conventional markers as creatine kinase [(CK); see Refs. (1)(2)]. Although CK is the most common serum marker for skeletal muscle injury, it is not ideal for several reasons, including lack of tissue specificity, inability to reveal damage to specific skeletal fiber types (fast or slow), and inappropriately low values when glutathione concentrations are decreased because of liver or multiple-organ failure (3). Skeletal troponin I (sTnI), with its two distinct isoforms [fast (fsTnI) and slow (ssTnI)], like cTnI and cTnT, may have a similar advantage over conventional markers for detecting skeletal-muscle injury.
In 1996, Rama et al. (4) described an experimental immunoenzymatic assay for sTnI using antibodies that cross-react with both sTnI and cTnI. The assumption of the investigators was that the concentrations of cTnI in patients with skeletal injury would be negligible. Others have since used this assay (5)(6)(7). For example, Onuoha et al. (7) found that serum sTnI reflects the severity and type of orthopedic and soft tissue injury. However, because this assay does not differentiate between the two isoforms of sTnI, which have a sequence homology of
56%, information about selective damage to particular fiber types is unavailable. Posttranslational modifications to the analyte, such as degradation, are also undetected by this assay.
We applied our Western blotdirect serum
The following articles in journals at HighWire Press have cited this article:
![]() |
J. A. Simpson, R. Labugger, C. Collier, R. J. Brison, S. Iscoe, and J. E. Van Eyk Fast and Slow Skeletal Troponin I in Serum from Patients with Various Skeletal Muscle Disorders: A Pilot Study Clin. Chem., June 1, 2005; 51(6): 966 - 972. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. O'Connell, D. G. Stephenson, R. Blazev, and G. M. M. Stephenson Troponin C isoform composition determines differences in Sr2+-activation characteristics between rat diaphragm fibers Am J Physiol Cell Physiol, July 1, 2004; 287(1): C79 - C87. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Simpson, J. Van Eyk, and S. Iscoe Respiratory muscle injury, fatigue and serum skeletal troponin I in rat J. Physiol., February 1, 2004; 554(3): 891 - 903. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |